Burning Rock Biotech (NASDAQ:BNR) Issues Earnings Results

Burning Rock Biotech (NASDAQ:BNR) issued its earnings results on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.04, FiscalAI reports. The business had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.

Burning Rock Biotech Trading Down 9.8%

Shares of BNR stock opened at $8.18 on Wednesday. The company has a market cap of $86.05 million, a price-to-earnings ratio of -10.35 and a beta of 1.32. The stock has a 50 day simple moving average of $15.89 and a 200-day simple moving average of $21.29. Burning Rock Biotech has a 12-month low of $2.95 and a 12-month high of $41.72.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech has an average rating of “Sell”.

Insiders Place Their Bets

In other news, Director Yusheng Han acquired 314,870 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average cost of $17.36 per share, with a total value of $5,466,143.20. Following the purchase, the director directly owned 17,672,676 shares of the company’s stock, valued at approximately $306,797,655.36. This trade represents a 1.81% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 30.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Marshall Wace LLP acquired a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned approximately 0.10% of Burning Rock Biotech at the end of the most recent reporting period. Institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.